Effect of spergualin in autoimmune disease mice.
We investigated the effect of spergualin (SGL) upon the development of spontaneous systemic lupus erythematosus-like lesions in male MRL/MpJ-lpr/lpr mice. SGL was administered ip at doses of 2.5, 5 and 10 mg/kg to two groups of mice. One group received SGL prophylactically from 7 to 21 weeks of age. The other group received SGL curatively from 13 to 27 weeks of age. The occurrence of lupus lesions was characterized by enlarged lymphoid organs, high anti-DNA titer and blood urea nitrogen, and severe glomerular nephritis. In both groups these characteristics were significantly suppressed by SGL in a dose-dependent manner. This inhibitory activity was greatest at a dose of 10 mg/kg. These findings suggest that SGL has prophylactic and curative effects against lupus lesions in autoimmune disease in mice.
Nemoto
K
K
Research Laboratories, Nippon Kayaku Co., Ltd., Tokyo, Japan.
Hayashi
M
M
Ito
J
J
Abe
F
F
Takita
T
T
Nakamura
T
T
Takeuchi
T
T
Umezawa
H
H
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D004247:DNA / Q000276:immunology; D006146:Guanidines / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy*; D008297:Male; D051379:Mice
D000903:Antibiotics, Antineoplastic; D006146:Guanidines; D007166:Immunosuppressive Agents; C033797:spergualin; D004247:DNA